Figure 2.

Schematic diagram of the present ADA-tolerant ADC assay. For assay configuration, the test sample containing the exatecan-based ADC and ADAs is first acidified. The ADAs are then removed by immune-affinity binding to the naked antibody coated on a microplate after the neutralization of acid-treated samples. Thereafter, the exatecan-based ADC molecules are captured by an anti-payload antibody coated on another microplate and measured with the detection reagent composed of His-tagged antigen and HRP-labeled anti-His antibody.